Further proof of a paradoxical relationship between high-density lipoprotein levels and adverse cardiovascular outcomes: are there implications for cardiovascular disease prevention?

被引：4

作者：

Kunutsor, Setor K. ^{[1
]}

Laukkanen, Jari A. ^{[2
,3
,4
]}

机构：

[1] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Gwendolen Rd, Leicester LE5 4WP, England

[2] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Yliopistonranta 1C, Canthia Bldg, B wing, FI-70211 Kuopio, Finland

[3] Univ Eastern Finland, Kuopio Univ Hosp, Inst Clin Med, Dept Med, Yliopistonranta 1 C, Canth Bldg, B wing, FI-70029 Kuopio, Finland

[4] Cent Finland Hlth Care Dist, Dept Med, Jyvaskyla 40620, Finland

来源：

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2023年 / 30卷 / 04期

关键词：

APOLIPOPROTEIN-A-I; RISK-FACTORS; CHOLESTEROL; HDL; MORTALITY; LIPIDS;

D O I：

10.1093/eurjpc/zwac272

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This editorial refers to 'U-shaped relationship between apolipoprotein A1 levels and mortality risk in men and women', by C.C. Faaborg-Andersen et al. https://doi.org/ 10.1093/eurjpc/zwac263.

引用

页码：290 / 292

页数：3

共 50 条

[31] New perspectives on the high-density lipoprotein system and its role in the prevention and treatment of atherosclerotic cardiovascular disease
Lan, Nick S. R.
Watts, Gerald F.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2025, 32 (02) : 66 - 74
[32] High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis
Favari, Elda
Thomas, Michael J.
Sorci-Thomas, Mary G.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 71 (06) : 325 - 331
[33] Cardiovascular Event Risk High-Density Lipoprotein and Paraoxonase
Superko, H. Robert
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (14) : 1246 - 1248
[34] High-density lipoprotein cholesterol and cardiovascular mortality: a prospective cohort study among 15.8 million adults
Yi, Sang-Wook
Park, Hyung Bok
Jung, Mi-Hyang
Yi, Jee-Jeon
Ohrr, Heechoul
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (05) : 844 - 854
[35] Is high-density lipoprotein a modifiable treatment target or just a biomarker for cardiovascular disease?
Whyte, Martin B.
JRSM CARDIOVASCULAR DISEASE, 2019, 8
[36] High-Density Lipoprotein Cholesterol and Cardiovascular Disease in Spanish Hypertensive Women. The RIMHA Study
Coca, Antonio
Cea-Calvo, Luis
Lozano, Jose V.
Inaraja, Veronica
Fernandez-Perez, Cristina
Navarro, Jorge
Bonet, Alvaro
Redon, Josep
REVISTA ESPANOLA DE CARDIOLOGIA, 2009, 62 (09): : 1022 - 1031
[37] Association between Mycoplasma pneumoniae infection, high-density lipoprotein metabolism and cardiovascular health (Review)
Shen, Tao
Li, Yanfang
Liu, Tingting
Lian, Yunzhi
Kong, Luke
BIOMEDICAL REPORTS, 2024, 20 (03)
[38] Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease
Besler, Christian
Luescher, Thomas F.
Landmesser, Ulf
EMBO MOLECULAR MEDICINE, 2012, 4 (04) : 251 - 268
[39] Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease
Haas, Michael J.
Mooradian, Arshag D.
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2010, 26 (02) : 90 - 99
[40] Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease
Zewinger, Stephen
Kleber, Marcus E.
Rohrer, Lucia
Lehmann, Marlene
Triem, Sarah
Jennings, Richard T.
Petrakis, Ioannis
Dressel, Alexander
Lepper, Philipp M.
Scharnagl, Hubert
Ritsch, Andreas
Thorand, Barbara
Heier, Margit
Meisinger, Christa
Gala, Tonia de las Heras
Koenig, Wolfgang
Wagenpfeil, Stefan
Schwedhelm, Edzard
Boger, Rainer H.
Laufs, Ulrich
von Eckardstein, Arnold
Landmesser, Ulf
Luscher, Thomas F.
Fliser, Danilo
Marz, Winfried
Meinitzer, Andreas
Speer, Thimoteus
EUROPEAN HEART JOURNAL, 2017, 38 (20) : 1597 - 1607

← 1 2 3 4 5 →